Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DiNAK-004
- Development stage
- Unknown
- Lead developer
- DiNAQOR
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
DiNAK-004 (also known as DF6234 or GS-6234) is a tri-specific natural killer (NK) cell engager therapy (TriNKET) developed by Dragonfly Therapeutics and licensed to Gilead Sciences. It is designed to target B7-H3 (CD276), a checkpoint molecule overexpressed in various solid tumors, including lung, prostate, and breast cancers. The TriNKET platform works by simultaneously binding to the tumor antigen (B7-H3) and activating NK cells through the engagement of both CD16a and NKG2D receptors. This dual activation of NK cells, combined with the recruitment of the adaptive immune system, aims to enhance anti-tumor activity compared to traditional monoclonal antibodies. Gilead Sciences acquired the exclusive global rights to DF6234 in 2022 to expand its oncology pipeline and is currently evaluating the asset in Phase 1 clinical trials.
- Other names
- B7-H3 TriNKETB-7-H3 TriNKETB 7-H3 TriNKET
02
Targets
B7-H3FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)NKG2D (Natural killer group 2 member D receptor)
Beyond the preview
Go deeper on DiNAK-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DiNAK-004.